See more : Tikehau Capital (0RP0.L) Income Statement Analysis – Financial Results
Complete financial analysis of Lantheus Holdings, Inc. (LNTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lantheus Holdings, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- RenoWorks Software Inc. (RW.V) Income Statement Analysis – Financial Results
- Crown Castle Inc. (CCI) Income Statement Analysis – Financial Results
- ZF Steering Gear (India) Limited (ZFSTEERING.BO) Income Statement Analysis – Financial Results
- Rane Engine Valve Limited (RANEENGINE.BO) Income Statement Analysis – Financial Results
- Oron Group Investments & Holdings Ltd (ORON.TA) Income Statement Analysis – Financial Results
Lantheus Holdings, Inc. (LNTH)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.lantheus.com
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.30B | 935.06M | 425.21M | 339.41M | 347.34M | 343.37M | 331.38M | 301.85M | 293.46M | 301.60M | 283.67M | 288.11M | 356.29M |
| Cost of Revenue | 586.89M | 353.36M | 237.51M | 200.65M | 172.53M | 168.49M | 169.24M | 164.07M | 157.94M | 176.08M | 206.31M | 212.91M | 261.08M |
| Gross Profit | 709.54M | 581.70M | 187.70M | 138.76M | 174.81M | 174.89M | 162.14M | 137.78M | 135.52M | 125.52M | 77.36M | 75.20M | 95.22M |
| Gross Profit Ratio | 54.73% | 62.21% | 44.14% | 40.88% | 50.33% | 50.93% | 48.93% | 45.64% | 46.18% | 41.62% | 27.27% | 26.10% | 26.72% |
| Research & Development | 77.71M | 311.68M | 44.97M | 32.79M | 20.02M | 17.07M | 18.13M | 12.20M | 14.36M | 13.67M | 30.46M | 40.60M | 40.95M |
| General & Administrative | 125.46M | 133.58M | 150.40M | 69.27M | 61.24M | 50.17M | 49.84M | 38.83M | 43.89M | 37.31M | 33.04M | 32.52M | 32.86M |
| Selling & Marketing | 141.74M | 100.24M | 68.42M | 40.90M | 41.89M | 43.16M | 42.32M | 36.54M | 34.74M | 35.12M | 35.23M | 37.44M | 38.69M |
| SG&A | 267.19M | 233.83M | 218.82M | 110.17M | 103.13M | 93.33M | 92.16M | 75.37M | 78.63M | 72.43M | 68.26M | 69.96M | 71.55M |
| Other Expenses | 0.00 | -1.70M | -7.35M | 2.20M | -6.22M | 2.47M | 8.64M | 220.00K | -89.00K | 3.00K | 9.25M | 34.80M | 205.00K |
| Operating Expenses | 344.90M | 545.51M | 263.78M | 142.96M | 123.15M | 110.40M | 110.28M | 87.58M | 92.99M | 86.10M | 98.72M | 110.56M | 112.50M |
| Cost & Expenses | 931.79M | 898.87M | 501.30M | 343.61M | 295.68M | 278.89M | 279.53M | 251.65M | 250.93M | 262.18M | 305.03M | 323.47M | 373.57M |
| Interest Income | 19.64M | 2.61M | 45.00K | 238.00K | 686.00K | 167.00K | 18.00K | 0.00 | 24.00K | 27.00K | 104.00K | 252.00K | 333.00K |
| Interest Expense | 20.02M | 7.19M | 7.75M | 9.48M | 13.62M | 17.41M | 18.41M | 26.62M | 38.72M | 42.29M | 42.92M | 42.01M | 37.66M |
| Depreciation & Amortization | 60.04M | 47.93M | 42.29M | 24.69M | 13.38M | 13.86M | 19.14M | 18.26M | 19.65M | 18.25M | 25.16M | 27.40M | 32.76M |
| EBITDA | 491.01M | 81.83M | -25.00M | 22.69M | 55.62M | 80.81M | 77.19M | 73.18M | 46.59M | 58.17M | 7.53M | 26.86M | 17.74M |
| EBITDA Ratio | 37.87% | 3.69% | -19.62% | -0.59% | 13.08% | 19.50% | 18.25% | 16.70% | 14.47% | 19.13% | 4.63% | 9.40% | 4.50% |
| Operating Income | 364.64M | -13.44M | -76.09M | -4.20M | 32.06M | 64.49M | 51.85M | 56.59M | 42.53M | 39.42M | -18.89M | -750.00K | -17.28M |
| Operating Income Ratio | 28.13% | -1.44% | -17.89% | -1.24% | 9.23% | 18.78% | 15.65% | 18.75% | 14.49% | 13.07% | -6.66% | -0.26% | -4.85% |
| Total Other Income/Expenses | 46.30M | -9.48M | -14.21M | -7.28M | -23.03M | -14.94M | -12.21M | -28.29M | -54.31M | -41.78M | -41.65M | -7.19M | -35.90M |
| Income Before Tax | 410.94M | 26.72M | -75.04M | -11.48M | 28.63M | 49.55M | 39.64M | 28.29M | -11.78M | -2.37M | -60.54M | -42.56M | -53.18M |
| Income Before Tax Ratio | 31.70% | 2.86% | -17.65% | -3.38% | 8.24% | 14.43% | 11.96% | 9.37% | -4.01% | -0.78% | -21.34% | -14.77% | -14.92% |
| Income Tax Expense | 84.28M | -1.35M | -3.76M | 1.99M | -3.04M | 9.03M | -83.75M | 1.53M | 2.97M | 1.20M | 1.01M | -555.00K | 84.08M |
| Net Income | 326.66M | 28.07M | -71.28M | -13.47M | 31.67M | 40.52M | 123.39M | 26.76M | -14.75M | -3.56M | -61.56M | -42.00M | -137.26M |
| Net Income Ratio | 25.20% | 3.00% | -16.76% | -3.97% | 9.12% | 11.80% | 37.23% | 8.87% | -5.02% | -1.18% | -21.70% | -14.58% | -38.52% |
| EPS | 4.79 | 0.41 | -1.06 | -0.25 | 0.81 | 1.06 | 3.31 | 0.84 | -0.60 | -0.20 | -3.40 | -2.36 | -7.61 |
| EPS Diluted | 4.65 | 0.40 | -1.06 | -0.25 | 0.79 | 1.03 | 3.17 | 0.82 | -0.60 | -0.20 | -3.34 | -2.32 | -7.61 |
| Weighted Avg Shares Out | 68.27M | 68.49M | 67.49M | 54.13M | 38.99M | 38.23M | 37.28M | 32.04M | 24.44M | 17.81M | 18.08M | 17.79M | 18.03M |
| Weighted Avg Shares Out (Dil) | 70.24M | 70.67M | 67.49M | 54.13M | 40.11M | 39.50M | 38.89M | 32.66M | 24.44M | 18.08M | 18.40M | 18.08M | 18.03M |
Wall Street Analysts See a 44.13% Upside in Lantheus Holdings (LNTH): Can the Stock Really Move This High?
Wall Street Analysts See Lantheus Holdings (LNTH) as a Buy: Should You Invest?
Lantheus' (LNTH) DEFINITY Approved by FDA for Pediatric Use
Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
Lantheus Holdings, Inc. (LNTH) Is a Trending Stock: Facts to Know Before Betting on It
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio
Lantheus to Present at the TD Cowen 44th Annual Health Care Conference
Lantheus (LNTH) Q4 Earnings Surpass Estimates, Gross Margin Up
Lantheus Holdings (LNTH) Recently Broke Out Above the 50-Day Moving Average
Source: https://incomestatements.info
Category: Stock Reports